Scientific publications

SEOM guidelines for the management of Malignant Melanoma 2015

Dec 1, 2015 | Magazine: Clinical & Translational Oncology

Berrocal A (1), Arance A (2), Espinosa E (3), Castaño AG (4), Cao MG (5), Larriba JL (6), Martín JA (7), Márquez I (8), Soria A (9), Algarra SM (10).


All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors.

Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy.

Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.

CITATION  Clin Transl Oncol. 2015 Dec;17(12):1030-5. doi: 10.1007/s12094-015-1450-4. Epub 2015 Dec 15.